Double-blind, placebo-controlled evaluation of biorest liposomal alendronate in diabetic patients undergoing PCI: The BLADE-PCI trial

• Published in: The American heart journal 2022-07, Vol.249, p.45-56
• Main Authors: Généreux, Philippe, Chernin, Gil, Assali, Abid R., Peruga, Jan Z., Robinson, Simon D., Schampaert, Erick, Bagur, Rodrigo, Mansour, Samer, Rodés-Cabau, Josep, McEntegart, Margaret, Gerber, Robert, L'Allier, Philippe, de Silva, Ranil, Daneault, Benoit, Aggarwal, Suneil K., Džavík, Vladimír, Ozan, M. Ozgu, Ben-Yehuda, Ori, Maehara, Akiko, Stone, Gregg W., Jonas, Michael
• Format: Article
• Language: English
• Subjects: Alendronate; Alendronic acid; Angioplasty; Animal models; Bisphosphonates; Clinical trials; Coronary Angiography - methods; Coronary Artery Disease - complications; Coronary Artery Disease - diagnosis; Coronary Artery Disease - surgery; Diabetes; Diabetes Mellitus; Double-blind studies; Drug delivery; Drug delivery systems; Drug dosages; Drug-Eluting Stents; Heart attacks; Humans; Hyperplasia; Implants; Insulin; Intravenous administration; Neointima - etiology; Optical Coherence Tomography; Patients; Percutaneous Coronary Intervention - methods; Placebos; Stents; Struts; Tomography; Tomography, Optical Coherence; Toxicity; Treatment Outcome
• ISSN: 0002-8703; 1097-6744
• DOI: 10.1016/j.ahj.2022.03.004

Diabetes mellitus (DM) is an important predictor of neointimal hyperplasia (NIH) and adverse clinical outcomes after percutaneous coronary intervention (PCI). LABR-312, a novel intravenous formulation of liposomal alendronate, has been shown in animal models to decrease NIH at vascular injury sites and around stent struts. The aim of the Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention trial was to assess the safety, effectiveness, and dose response of LABR-312 administered intravenously at the time of PCI withDES in reducing NIH as measured by optical coherence tomography postprocedure in patients with DM. Patients with DM were randomized to a bolus infusion of LABR-312 vs placebo at the time of PCI. Dose escalation of LABR-312 in the study arm was given: 0.01 mg, 0.03 mg, and 0.08 mg. The primary endpoint was the in-stent %NIH volume at 9 months as measured by optical coherence tomography. From September 2016 to December 2017, 271 patients with DM undergoing PCI were enrolled; 136 patients were randomized to LABR-312 infusion and 135 patients were randomized to placebo. At 9-month follow-up, no difference was seen in the primary endpoint of %NIH between LABR-312 and placebo (13.3% ± 9.2 vs 14.6% ± 8.5, P = .35). No differences were present with the varying LABR-312 doses. Clinical outcomes at 9 months were similar between groups. Among patients with DM undergoing PCI with drug-eluting stents, a bolus of LABR-312 injected systematically at the time of intervention did not result in a lower rate in-stent %NIH volume at 9-month follow-up.